|Project Title||Principal Investigator||Institution|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders -2||Nakanishi, Nobuki||Burnham Institute|
|Interaction between MEF2 and MECP2 in the pathogenesis of autism spectrum disorders - 1||Lipton, Stuart||Burnham Institute|
|Integrated approach to the neurobiology of autism spectrum disorders||Vaccarino, Flora||Yale University|
|Insight into MeCP2 function raises therapeutic possibilities for Rett syndrome||Lomvardas, Stavros||University of California, San Francisco|
|Identifying impairments in synaptic connectivity in mouse models of ASD||Speed, Haley||University of Texas Southwestern Medical Center|
|Identifying genetic modifiers of rett syndrome in the mouse||Buchovecky, Christine||Baylor College of Medicine|
|Identification of autism genes that regulate synaptic Nrx/Nlg signaling complexes||Garner, Craig||Stanford University|
|High-resolution diffusion tensor imaging in mouse models relevant to autism||Poptani, Harish||University of Pennsylvania|
|High content screens of neuronal development for autism research||Halpain, Shelley||University of California, San Diego|
|Genomic resources for identifying genes regulating social behavior||Young, Larry||Emory University|
|Genomic imbalances at the 22q11 locus and predisposition to autism||Gogos, Joseph||Columbia University|
|Genetic models of serotonin transporter regulation linked to mental disorders||Ramamoorthy, Sammanda||Medical University of South Carolina|
|Function and dysfunction of neuroligins||Sudhof, Thomas||Stanford University|
|Functional study of synaptic scaffold protein SHANK3 and autism mouse model||Jiang, Yong-Hui||Duke University|
|Functional genomic dissection of language-related disorders||Fisher, Simon||University of Oxford|
|Exploring the neuronal phenotype of autism spectrum disorders using induced pluripotent stem cells||Hallmayer, Joachim; Dolmetsch, Ricardo||Stanford University|
|Evaluation of altered fatty acid metabolism via gas chromatography/mass spectroscopy and time-of-flight secondary ion mass spectroscopy imaging in the propionic acid rat model of autism spectrum disorders||MacFabe, Derrick||University of Western Ontario|
|Dynamic regulation of Shank3 and ASD||Worley, Paul||Johns Hopkins University|
|Dissecting the neural control of social attachment||Shah, Nirao||University of California, San Francisco|
|Dissecting the circuitry basis of autistic-like behaviors in mice||Feng, Guoping||Massachusetts Institute of Technology|
|Development of a high-content neuronal assay to screen therapeutics for the treatment of cognitive dysfunction in autism spectrum disorders||Bear, Mark||Massachusetts Institute of Technology|
|Deriving neuroprogenitor cells from peripheral blood of individuals with autism||Fujinami, Robert||University of Utah|
|Control of synaptic protein synthesis in the pathogenesis and therapy of autism||Kelleher, Raymond||Massachusetts General Hospital|
|Cntnap2 in a behavioral model of autism||White, Stephanie||University of California, Los Angeles|
|Characterization of the transcriptome in an emerging model for social behavior||Thomas, James||Emory University|
|IACC Strategic Plan Objective||2008||2009||2010||2011||2012||Total|
|Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012.
IACC Recommended Budget: $75,000,000 over 5 years
|4.S.B. Funding: The recommended budget was met. Significantly more than the recommended minimum budget was allocated to projects specific to this objective.
Progress: More than 90 projects were supported to develop animal models.
Remaining Gaps, Needs, and Opportunities: Planning Group members discussed whether the amount of investment in this area is appropriate when compared to investments in clinical trials and other later stage studies. Invited experts suggested that the current stage of scientific research in ASD requires pre-clinical research to identify targets from animal and cellular models. Similar to cancer treatment development pathways, which spanned 20-30 years, research in ASD must invest in model systems to understand the fundamental biology from which translation to the clinic can be built. The translational validity of research in non-human animals cannot be determined until human trials are conducted, thus the need for rapid progress to clinical studies in humans is important.